Kaplan Matthew L. 4
4 · Nuvectis Pharma, Inc. · Filed May 16, 2022
Insider Transaction Report
Form 4
Kaplan Matthew L.
Director
Transactions
- Purchase
Common Stock
2022-05-12$15.96/sh+1,177$18,785→ 33,937 total - Purchase
Common Stock
2022-05-12$17.47/sh+1,823$31,848→ 35,760 total
Footnotes (2)
- [F1]Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.75 to $16.00. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.33 to $17.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.